{
 "drug": "Gemcitabine Hydrochloride Injection",
 "asOf": "2026-08-25",
 "status": "discontinuing",
 "since": "09/11/2025",
 "dayN": 348,
 "cat": "Oncology",
 "companies": [
  "Hospira, Inc., a Pfizer Company"
 ],
 "reasons": [],
 "records": [
  {
   "discontinued_date": "09/11/2025",
   "update_type": "New",
   "initial_posting_date": "09/11/2025",
   "package_ndc": "0409-0181-25",
   "generic_name": "Gemcitabine Hydrochloride Injection",
   "contact_info": "844-646-4398",
   "related_info": "Discontinuation of the manufacture of the drug",
   "openfda": {
    "application_number": [
     "NDA200795"
    ],
    "brand_name": [
     "GEMCITABINE"
    ],
    "generic_name": [
     "GEMCITABINE"
    ],
    "manufacturer_name": [
     "Hospira, Inc."
    ],
    "product_ndc": [
     "0409-0181",
     "0409-0183",
     "0409-0182"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "INTRAVENOUS"
    ],
    "substance_name": [
     "GEMCITABINE HYDROCHLORIDE"
    ],
    "rxcui": [
     "1720960",
     "1720975",
     "1720977"
    ],
    "spl_id": [
     "3a284abb-8c57-47dc-a138-5a6e6ab92b05",
     "c0f06508-36d7-4325-a425-707d254d185b"
    ],
    "spl_set_id": [
     "dc02a23b-3ff9-4441-aa91-8e9e629a7315",
     "e18ed1cb-7dd0-4001-bfda-17d1f4587fb8"
    ],
    "package_ndc": [
     "0409-0181-01",
     "0409-0183-01",
     "0409-0182-01",
     "0409-0181-25",
     "0409-0182-25",
     "0409-0183-25"
    ],
    "unii": [
     "U347PV74IL"
    ]
   },
   "update_date": "09/11/2025",
   "therapeutic_category": [
    "Oncology"
   ],
   "dosage_form": "Injection",
   "presentation": "Gemcitabine Hydrochloride, Injection, 1 g/26.3 mL (38 mg/mL), sterile solution in a single-dose glass vial  NovaPlus (NDC 0409-0181-25)",
   "company_name": "Hospira, Inc., a Pfizer Company",
   "status": "To Be Discontinued"
  },
  {
   "discontinued_date": "09/11/2025",
   "update_type": "New",
   "initial_posting_date": "09/11/2025",
   "package_ndc": "0409-0183-25",
   "generic_name": "Gemcitabine Hydrochloride Injection",
   "contact_info": "844-646-4398",
   "related_info": "Discontinuation of the manufacture of the drug",
   "openfda": {
    "application_number": [
     "NDA200795"
    ],
    "brand_name": [
     "GEMCITABINE"
    ],
    "generic_name": [
     "GEMCITABINE"
    ],
    "manufacturer_name": [
     "Hospira, Inc."
    ],
    "product_ndc": [
     "0409-0183",
     "0409-0181",
     "0409-0182"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "INTRAVENOUS"
    ],
    "substance_name": [
     "GEMCITABINE HYDROCHLORIDE"
    ],
    "rxcui": [
     "1720960",
     "1720975",
     "1720977"
    ],
    "spl_id": [
     "3a284abb-8c57-47dc-a138-5a6e6ab92b05",
     "c0f06508-36d7-4325-a425-707d254d185b"
    ],
    "spl_set_id": [
     "dc02a23b-3ff9-4441-aa91-8e9e629a7315",
     "e18ed1cb-7dd0-4001-bfda-17d1f4587fb8"
    ],
    "package_ndc": [
     "0409-0181-01",
     "0409-0183-01",
     "0409-0182-01",
     "0409-0181-25",
     "0409-0182-25",
     "0409-0183-25"
    ],
    "unii": [
     "U347PV74IL"
    ]
   },
   "update_date": "09/11/2025",
   "therapeutic_category": [
    "Oncology"
   ],
   "dosage_form": "Injection",
   "presentation": "Gemcitabine Hydrochloride, Injection, 200 mg/5.26 mL (38 mg/mL), sterile solution in a single-dose glass vial NovaPlus (NDC 0409-0183-25)",
   "company_name": "Hospira, Inc., a Pfizer Company",
   "status": "To Be Discontinued"
  },
  {
   "discontinued_date": "09/11/2025",
   "update_type": "New",
   "initial_posting_date": "09/11/2025",
   "package_ndc": "0409-0182-25",
   "generic_name": "Gemcitabine Hydrochloride Injection",
   "contact_info": "844-646-4398",
   "related_info": "Discontinuation of the manufacture of the drug",
   "openfda": {
    "application_number": [
     "NDA200795"
    ],
    "brand_name": [
     "GEMCITABINE"
    ],
    "generic_name": [
     "GEMCITABINE"
    ],
    "manufacturer_name": [
     "Hospira, Inc."
    ],
    "product_ndc": [
     "0409-0182",
     "0409-0181",
     "0409-0183"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "INTRAVENOUS"
    ],
    "substance_name": [
     "GEMCITABINE HYDROCHLORIDE"
    ],
    "rxcui": [
     "1720960",
     "1720975",
     "1720977"
    ],
    "spl_id": [
     "3a284abb-8c57-47dc-a138-5a6e6ab92b05",
     "c0f06508-36d7-4325-a425-707d254d185b"
    ],
    "spl_set_id": [
     "dc02a23b-3ff9-4441-aa91-8e9e629a7315",
     "e18ed1cb-7dd0-4001-bfda-17d1f4587fb8"
    ],
    "package_ndc": [
     "0409-0181-01",
     "0409-0183-01",
     "0409-0182-01",
     "0409-0181-25",
     "0409-0182-25",
     "0409-0183-25"
    ],
    "unii": [
     "U347PV74IL"
    ]
   },
   "update_date": "09/11/2025",
   "therapeutic_category": [
    "Oncology"
   ],
   "dosage_form": "Injection",
   "presentation": "Gemcitabine Hydrochloride, Injection, 2 g/52.6 mL (38 mg/mL), sterile solution in a single-dose glass vial NovaPlus (NDC 0409-0182-25)",
   "company_name": "Hospira, Inc., a Pfizer Company",
   "status": "To Be Discontinued"
  }
 ]
}